Skip to content

The Safety and Efficacy of Stent Retriever for Recanalization in Acute Ischemic Stroke Therapy: a Prospective, Multicenter, Open Label, Blinded End Point, Stratified Random, Parallel Positive Controlled, Non-Inferiority Study

The Safety and Efficacy of Stent Retriever for Recanalization in Acute Ischemic Stroke Therapy: a Prospective, Multicenter, Open Label, Blinded End Point, Stratified Random, Parallel Positive Controlled, Non-Inferiority Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034307
Enrollment
Unknown
Registered
2020-07-01
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke caused by anterior circulation intracranial large vessel occlusion

Interventions

Experimental Device:Thrombactomy by Stent Retriever
Control Device:Thrombactomy by Solitaire FR

Sponsors

The First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years. 2. Symptoms and signs in accordance with anterior circulation ischemia and large vessel occlusion (ICA, MCA-M1 or M2) confirmed by DSA. 3. No obvious disability before onset (Pre-operation modified Rankin Scale(mRS)0-1). 4. NIHSS score >= 6 points at time of randomization. 5. Treatment can be started within 8 hours of onset (randomization complete). (If the onset time of the patient is unknown, for example, when the patient wakes up and finds stroke symptoms, the onset time is taken as the onset of sleep; the patient cannot express the time of onset due to new stroke symptoms such as aphasia and coma, and there are no witnesses beside him, then the time when the patient was last seen in the normal state is taken as the onset time). 6. Written informed consent obtained from patient or patient's legally authorized representative.

Exclusion criteria

Exclusion criteria: 1. Acute posterior circulation cerebral infarction confirmed by CT or MRI. 2. Any type of cerebral hemorrhage (only microbleeds are allowed) on CT or MRI. 3. ASPECTS 22.2 mmol/L. 12. Baseline blood pressure > 185/110 mmHg, or aggressive treatment (intravenous medication) necessary to reduce blood pressure to these limits. 13. Dementia or psychiatric disease that would confound the neurological or functional evaluations. 14. Life expectancy less than 1 year. 15. Current participation in another drug or device research. 16. Severe heart, liver or kidney failure and other serious or terminal illness, and the researchers believe to be not suitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Instant recanalization rate (mTICI 2b-3) of target vessel after the procedure;

Secondary

MeasureTime frame
Instant recanalization rate (mTICI 2b-3) after the first thrombectomy;Instant recanalization rate (mTICI 2b-3) after the last thrombectomy;The number of times of stent thrombectomy;The proportion of rescue therapy;Procedure time (randomization complete to recanalization);Change in NIHSS score from baseline at 24-48 hours;Change in NIHSS score from baseline at 7±1 days or discharge;Recanalization situation at 72 hours, as measured by ASPECTS on CT or MRI;The extent of anterior circulation infarction at 24±6 hours, as measured by ASPECTS on CT or MRI;Proportion of functional independence (mRS 0-2) at 90±10 days;Ordinal shift analysis of mRS at 90±10 days;

Countries

China

Contacts

Public ContactHuaizhang Shi

The First Affiliated Hospital of Harbin Medical University

Huaizhangshi@163.com+86 13936696959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026